Results 31 to 40 of about 19,741 (164)
Onboard, tethered IL-12 boosts potency of the Tmod NOT gate and preserves selectivity
Journal for ImmunoTherapy of CancerBackground To reach their full potential in cancer therapy, immune cells engineered with synthetic constructs must achieve the challenging dual objectives of potency and selectivity to overcome the key obstacle: non-specific cytotoxicity.Alexander Kamb, Sara Imboden, Dongwoo Lee, Mark E Daris, Alexandre Zampieri, Jingli A Zhang, Sanam Shafaattalab, Jushen Liang, Richele Bruno, Jon Torres, Alexander Partin, Timothy P Riley +11 moredoaj +1 more sourceA novel monoclonal antibody against human thymic stromal lymphopoietin for the treatment of TSLP-mediated diseases
Frontiers in ImmunologyIntroductionThymic stromal lymphopoietin (TSLP) is a master regulator of allergic inflammation against pathogens at barrier surfaces of the lung, skin, and gut.Lihua Shi, Mingcan Yu, Ying Jin, Peng Chen, Guangmao Mu, Susan H. Tam, Minseon Cho, Mark Tornetta, Chao Han, Man-Cheong Fung, Mark L. Chiu, Di Zhang +11 moredoaj +1 more sourceTNFa and IL-2 armed adenoviruses enable complete responses by anti-PD-1 checkpoint blockade
OncoImmunology, 2018 Releasing the patient's immune system against their own malignancy by the use of checkpoint inhibitors is delivering promising results. However, only a subset of patients currently benefit from them. One major limitation of these therapies relates to the V. Cervera-Carrascon, M. Siurala, J. M. Santos, R. Havunen, S. Tähtinen, P. Karell, S. Sorsa, A. Kanerva, A. Hemminki +8 moredoaj +1 more sourceMesothelin-specific CAR-T cell therapy that incorporates an HLA-gated safety mechanism selectively kills tumor cells
Journal for ImmunoTherapy of Cancer, 2022 Breanna DiAndreth, Kiran Deshmukh, Jee-Young Mock, Talar Tokatlian, Alexander Kamb, Shruti Sharma, Grace E Asuelime, Dora Toledo Warshaviak, Mark E Daris, Kristian Bolanos, Breanna L Luna, Martin S Naradikian, Agnes E Hamburger +12 moredoaj +1 more sourceA trispecific antibody targeting EGFR/cMET/VEGF-A demonstrates multiple mechanisms of action to inhibit wild-type and mutant NSCLC animal models
Frontiers in OncologyIntroductionNon-small cell lung cancer (NSCLC) patients who do not respond to standard of care treatment can have activating mutations in the epidermal growth factor receptor (EGFR) and mesenchymal epithelial transition factor (cMET) signaling pathways ...Ying Jin, Ping Sun, Peng Chen, Yuqiang Xu, Guangmao Mu, Zhengxia Zha, Simin Wu, Meixia Fu, Hao Jiang, Sheng Huang, Fulai Zhou, Chao Han, Chao Han, Mark L. Chiu, Mark L. Chiu +14 moredoaj +1 more source1355 DM919, an IND-ready MICA/B-specific antibody, reinforces NKG2D-MICA/B axis and promotes anti-tumor activities
Journal for ImmunoTherapy of Cancer, 2023 Yi Xu, Dong Zhang, Nan Bing, Hong Chang, Sheng Yin, Guangan Hu, Quanju Zhao, Xiaochun Chen, Xiaodong Jiang +8 moredoaj +1 more source784 BDC-2034: discovery of a CEA-targeting immune-stimulating antibody conjugate (ISAC) for solid tumors
Journal for ImmunoTherapy of Cancer, 2021 Marcin Kowanetz, Shelley Ackerman, David Dornan, Michael Alonso, Edith Perez, Cecelia Pearson, Arthur Lee, Karla Henning, Steven Chapin, LIsa Blum, Angela Luo, Matthew Zhou, Brian Safina, Amreen Husain, William Mallet, Rishali Gadkari, Laughing Bear Torrez Dulgeroff, AAngela Luondrew Luo, Jennifer Melrose, Jess Nolin, Puneet Anand, Ganapathy Sarma, Liz Bogaert, Romas Kudirka, Yuyi Shen +24 moredoaj +1 more source821 The combination of a trastuzumab ISAC and pertuzumab augments anti-tumor efficacy in multiple HER2+ tumor models relative to trastuzumab plus pertuzumab
Journal for ImmunoTherapy of Cancer, 2023 Edith A Perez, Andrew Luo, Anthony Lucas, Han K Kim, Paul D Ponath, Katelynn A McEachin, Karla A Henning, Shelley E Ackerman, Steven J Chapin, Michael N Alonso, Cecelia I Pearson, David Omstead +11 moredoaj +1 more source
